knowledge -WSS

knowledge

author：explore 2025-09-03 03:46:11 - browse：24159

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： A new study sees potential in DNA sequencing of infants

knowledge

WSS

Iowa House, Senate pass 6

Beach reads and more: STAT's 2023 summer book list

Why ADHD is under

Study: Pain burden is higher in Black NFL players than white ones

Cancer, immunology, HIV research ensnared in fetal tissue politics

Surgeons perform first xenotransplant using CRISPR'd pig kidney

hotspot

knowledge

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Mirador, a new biotech startup, launches with $400 million

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Drug repurposing or repositioning? The language matters

With Wegovy coverage, Medicare patients may face high costs

Alkermes shareholders re

Bring on the sabbaticals for nurses

How one medical school became remarkably diverse

Pregnancy ages women, but effects reverse after delivery

entertainment

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Elizabeth Holmes on track for early release from her 11

U.K. officials, researchers try to ease path for bespoke genetic treatments

Lecanemab for Alzheimer's is coming. Is the health system ready?

Cancer, immunology, HIV research ensnared in fetal tissue politics

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

leisure time

focus

knowledge

hotspot